162 related articles for article (PubMed ID: 35349261)
21. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
Al Batran R; Almutairi M; Ussher JR
Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
[TBL] [Abstract][Full Text] [Related]
22. Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents.
Yang Q; Zhou F; Tang X; Wang J; Feng H; Jiang W; Jin L; Jiang N; Yuan Y; Han J; Yan Z
Eur J Med Chem; 2022 Apr; 233():114214. PubMed ID: 35231829
[TBL] [Abstract][Full Text] [Related]
23. Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.
Cheong YH; Kim MK; Son MH; Kaang BK
Biochem Biophys Res Commun; 2012 Jan; 417(1):558-63. PubMed ID: 22177947
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 receptor action in the vasculature.
Almutairi M; Al Batran R; Ussher JR
Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
[TBL] [Abstract][Full Text] [Related]
25. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
26. A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities.
He M; Guan N; Gao WW; Liu Q; Wu XY; Ma DW; Zhong DF; Ge GB; Li C; Chen XY; Yang L; Liao JY; Wang MW
Acta Pharmacol Sin; 2012 Feb; 33(2):148-54. PubMed ID: 22301855
[TBL] [Abstract][Full Text] [Related]
27. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
28. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
Foer D; Beeler PE; Cui J; Karlson EW; Bates DW; Cahill KN
Am J Respir Crit Care Med; 2021 Apr; 203(7):831-840. PubMed ID: 33052715
[No Abstract] [Full Text] [Related]
29. Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist.
Li Y; Zheng X; Yi X; Liu C; Kong D; Zhang J; Gong M
FASEB J; 2017 Jun; 31(6):2603-2611. PubMed ID: 28270518
[TBL] [Abstract][Full Text] [Related]
30. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
31. Allosteric Modulators Enhancing GLP-1 Binding to GLP-1R via a Transmembrane Site.
Wang J; Yang D; Cheng X; Yang L; Wang Z; Dai A; Cai X; Zhang C; Yuliantie E; Liu Q; Jiang H; Liu H; Wang MW; Yang H
ACS Chem Biol; 2021 Nov; 16(11):2444-2452. PubMed ID: 34570476
[TBL] [Abstract][Full Text] [Related]
32. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
Chen D; Liao J; Li N; Zhou C; Liu Q; Wang G; Zhang R; Zhang S; Lin L; Chen K; Xie X; Nan F; Young AA; Wang MW
Proc Natl Acad Sci U S A; 2007 Jan; 104(3):943-8. PubMed ID: 17213311
[TBL] [Abstract][Full Text] [Related]
33. Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.
Cong Z; Chen LN; Ma H; Zhou Q; Zou X; Ye C; Dai A; Liu Q; Huang W; Sun X; Wang X; Xu P; Zhao L; Xia T; Zhong W; Yang D; Eric Xu H; Zhang Y; Wang MW
Nat Commun; 2021 Jun; 12(1):3763. PubMed ID: 34145245
[TBL] [Abstract][Full Text] [Related]
34. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
Conlon JM; O'Harte FPM; Flatt PR
Peptides; 2022 Jan; 147():170706. PubMed ID: 34861327
[TBL] [Abstract][Full Text] [Related]
35. Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
Li N; Lu J; Willars GB
PLoS One; 2012; 7(10):e47936. PubMed ID: 23094100
[TBL] [Abstract][Full Text] [Related]
36. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
Doggrell SA
Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389
[TBL] [Abstract][Full Text] [Related]
37. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity.
Usui R; Yabe D; Seino Y
J Diabetes Investig; 2019 Jul; 10(4):902-905. PubMed ID: 30637966
[TBL] [Abstract][Full Text] [Related]
38. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
39. Non-peptide agonists and positive allosteric modulators of glucagon-like peptide-1 receptors: Alternative approaches for treatment of Type 2 diabetes.
Malik F; Li Z
Br J Pharmacol; 2022 Feb; 179(4):511-525. PubMed ID: 33724441
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Drucker DJ
Cell Metab; 2018 Apr; 27(4):740-756. PubMed ID: 29617641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
